Upfront Briefing
UCB’s Bimzelx posted a head-to-head superiority win vs AbbVie’s Skyrizi in psoriatic arthritis — the kind of direct comp that can move share and reset the “best-in-class” talking points.
On the FDA front, leucovorin got cleared for ultra-rare cerebral folate deficiency, while Lilly outlined East Asia manufacturing expansion in China and South Korea to support launches and volume. Busy day for both the label and the supply chain.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,775.8 |
(0.1%) |
(1.2%) |
| Nasdaq 100 |
24,965.0 |
0.0% |
(1.0%) |
| Russell 2000 |
2,542.9 |
(0.2%) |
+2.5% |
| Healthcare (XLV) |
152.9 |
(0.2%) |
(1.7%) |
| Biotech (XBI) |
126.4 |
(0.8%) |
+4.0% |
| Nasdaq Biotech (NBI) |
5,905.4 |
(0.7%) |
+3.5% |
| Clinical Trials (BBC) |
43.0 |
(0.9%) |
+14.2% |
|
- Health/biotech lagged a mixed tape: XBI fell (0.8%) and NBI (0.7%) versus S&P 500 (0.1%), as rising oil and Iran-linked geopolitical risk kept investors out of higher-beta corners of the market.
- Nasdaq held roughly flat thanks to Oracle-led AI strength, but that support did not spill over into biotech; absent a fresh company-specific catalyst burst, investors rotated toward larger-cap tech rather than SMID-cap life science risk.
- BBC fell (0.9%), underlining the point: the more clinical-risk-heavy sleeve underperformed even as the broader index action looked orderly on the surface.
The Big 3
|
1
|
UCB's Bimzelx beats AbbVie's Skyrizi in psoriatic arthritis
|
-
UCB's Bimzelx demonstrated superiority over AbbVie's Skyrizi in a psoriatic arthritis trial, potentially impacting market share and pricing power for AbbVie's post-Humira growth strategy.
-
Why it matters: Head-to-head superiority data are rare and commercially potent. If Bimzelx can translate this into prescribing momentum, it strengthens UCB’s “best-in-class” argument in PsA while adding pressure to AbbVie’s Skyrizi narrative in one of its key post-Humira growth pillars.
-
Source:
BioCentury
-
More:
Endpoints
|
|
2
|
FDA clears leucovorin for ultra-rare cerebral folate deficiency
|
-
The FDA approved leucovorin for the ultra-rare condition cerebral folate deficiency, highlighting regulatory flexibility in a setting with high unmet need and limited conventional trial data.
-
Why it matters: The approval is narrow, but it still matters: it shows the FDA is willing to be flexible on evidence in ultra-rare settings when biology and case-report literature are compelling. For investors, that is a useful reminder that niche rare-disease assets can still reach value inflection without a conventional trial package.
-
Source:
BioPharma Dive
-
More:
STAT
|
| 3 | Eli Lilly expands East Asia manufacturing footprint |
-
Eli Lilly is expanding its East Asia manufacturing footprint with a new buildout in China and a pledge in South Korea, moves that support future launch readiness and regional supply capacity as its obesity franchise scales.
-
Why it matters: This is really an obesity-execution story. Expanding oral solid-dose capacity in China de-risks regional supply ahead of orforglipron, while the South Korea commitment deepens Lilly’s innovation footprint in a market that matters for both development partnerships and clinical infrastructure.
-
Source:
BioPharma Dive
-
More:
Endpoints
|
Everything Else that broke
- FDA merges adverse event trackers into one database. — Endpoints
- Biogen presents new data for Spinraza successor salanersen. — BioPharma Dive
- Novo Holdings' assets fall by a third in 2025. — Endpoints
- Evotec plans up to 800 job cuts and four site closures. — Endpoints
- FDA's risk tolerance for gene therapies amid cancer debate. — BioCentury
- Zealand/Roche's petrelintide focuses on tolerability in obesity. — BioCentury
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- George Medicines signed an exclusive Korea licensing and supply deal with Ahngook Pharmaceutical for GMRx2; terms include an upfront fee, regulatory/commercial milestones, and stepped royalties. — PR
VC / Private Financings
- Vima Therapeutics extended its Series A by $40M, bringing the round to $100M, alongside first patient dosed in Phase 2 for dystonia. Syndicate: new investor Frazier Life Sciences, joined by Atlas Venture, Access Industries, and Canaan Partners. — PR
IPOs / Follow-Ons
- No notable IPOs / Follow-Ons in the last 24 hours.
Academic Corner
- Engineered TnpB genome editors for plants and human cells identified by ribonucleoprotein mutational scanning. — Nature Biotech
- Clinical development of cancer vaccines. — Nature Medicine
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. — NEJM
- The promises and challenges of neoantigen cancer vaccines. — Nature Biotech
|
